Literature DB >> 15548764

Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.

Jiesheng Kang1, Xiao-Liang Chen, Hongge Wang, Junzhi Ji, Hsien Cheng, Josephine Incardona, William Reynolds, Fabrice Viviani, Michel Tabart, David Rampe.   

Abstract

Many drugs inhibit the human ether-a-go-go-related gene (HERG) cardiac K+ channel. This leads to action potential prolongation on the cellular level, a prolongation of the QT interval on the electrocardiogram, and sometimes cardiac arrhythmia. To date, no activators of this channel have been reported. Here, we describe the in vitro electrophysiological effects of (3R,4R)-4-[3-(6-methoxyquinolin-4-yl)-3-oxo-propyl]-1-[3-(2,3,5-trifluoro-phenyl)-prop-2-ynyl]-piperidine-3-carboxylic acid (RPR260243), a novel activator of HERG. Using patch-clamp electrophysiology, we found that RPR260243 dramatically slowed current deactivation when applied to cells stably expressing HERG. The effects of RPR260243 on HERG channel deactivation were temperature- and voltage-dependent and occurred over the concentration range of 1 to 30 microM. RPR260243-modified HERG currents were inhibited by dofetilide (IC50 = 58 nM). RPR260243 had little effect on HERG current amplitude and no significant effects on steady-state activation parameters or on channel inactivation processes. RPR260243 displayed no activator-like effects on other voltage-dependent ion channels, including the closely related erg3 K+ channel. RPR260243 enhanced the delayed rectifier current in guinea pig myocytes but, when administered alone, had little effect on action potential parameters in these cells. However, RPR260243 completely reversed the action potential-prolonging effects of dofetilide in this preparation. Using the Langendorff heart method, we found that 5 microM RPR260243 increased T-wave amplitude, prolonged the PR interval, and shortened the QT interval. We believe RPR260243 represents the first known HERG channel activator and that the drug works primarily by inhibiting channel closure, leading to a persistent HERG channel current upon repolarization. Compounds like RPR260243 will be useful for studying the physiological role of HERG and may one day find use in treating cardiac disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15548764     DOI: 10.1124/mol.104.006577

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  53 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

Review 2.  HERG1 channelopathies.

Authors:  Michael C Sanguinetti
Journal:  Pflugers Arch       Date:  2009-11-22       Impact factor: 3.657

3.  Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a/Kv11.1b channels.

Authors:  A P Larsen; B H Bentzen; M Grunnet
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 4.  hERG quality control and the long QT syndrome.

Authors:  Brian Foo; Brittany Williamson; Jason C Young; Gergely Lukacs; Alvin Shrier
Journal:  J Physiol       Date:  2016-02-09       Impact factor: 5.182

Review 5.  Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

7.  Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.

Authors:  Morten Grunnet; Jennifer Abbruzzese; Frank B Sachse; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2010-09-27       Impact factor: 4.436

8.  Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator.

Authors:  Matthew Perry; Frank B Sachse; Michael C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-10       Impact factor: 11.205

Review 9.  Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

Authors:  Rashmi R Shah
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

10.  Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.

Authors:  Matthew D Perry; Chai Ann Ng; Kevin Phan; Erikka David; Kieran Steer; Mark J Hunter; Stefan A Mann; Mohammad Imtiaz; Adam P Hill; Ying Ke; Jamie I Vandenberg
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.